AlloVir, Inc.

NasdaqCM ALVR

AlloVir, Inc. Current Liabilities for the quarter ending September 30, 2024

AlloVir, Inc. Current Liabilities is NA for the quarter ending September 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

AlloVir, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 33.07 M, a 59.59% change year over year.
AlloVir, Inc. Current Liabilities for the quarter ending September 30, 2022 was USD 20.72 M, a -14.29% change year over year.
AlloVir, Inc. Current Liabilities for the quarter ending September 30, 2021 was USD 24.17 M, a 78.78% change year over year.
AlloVir, Inc. Current Liabilities for the quarter ending September 30, 2020 was USD 13.52 M.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqCM: ALVR

AlloVir, Inc.

CEO	Dr. Diana M. Brainard M.D.
IPO Date	July 30, 2020
Location	United States
Headquarters	1100 Winter Street
Employees	8
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Key trends

Past 5 years